Shimazu, Y
Kurozumi, K
Ichikawa, T
Fujii, K
Onishi, M
Ishida, J
Oka, T
Watanabe, M
Nasu, Y
Kumon, H
Date, I
Article History
Received: 9 April 2014
Revised: 24 September 2014
Accepted: 6 October 2014
First Online: 13 November 2014
Competing interests
: Momotaro-Gene Inc. holds the patents of the Ad-REIC agent and develops the agent as a cancer therapeutic medicine. Dr Kumon, Dr Nasu and Dr Watanabe demonstrated the utility of the agent and also own the stock in Momotaro-Gene Inc. Okayama University and Momotaro-Gene Inc. are working together for the development of the Ad-REIC agent. Okayama University received the GMP-grade Ad-REIC agent from Momotaro-Gene Inc. to perform the clinical trials for the treatment of cancer patients. Okayama University also received research funds for the joint research. Dr Kumon is the Chief Science Officer in Momotaro-Gene Inc.